Publications by authors named "T Klopsch"
Article Synopsis
- Etanercept (ETN) was studied in a real-world setting to evaluate its effects on radiographic progression in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) over a treatment period of up to 36 months in Germany.
- The study involved 1821 patients and found that the mean modified total Sharp score (mTSS) remained stable during treatment, indicating less radiographic progression compared to the pre-treatment phase, especially in patients with prior radiographic data.
- Overall, the findings suggest that ETN slows radiographic progression in RA and PsA, as demonstrated by a higher rate of non-progression during treatment and improvements in clinical disease activity and patient
Background: For rheumatoid arthritis (RA), the treat-to-target concept suggests attaining remission or at least low disease activity (LDA) after 12 weeks.
Objectives: This German, prospective, multicenter, non-interventional study aimed to determine the proportion of patients with RA who achieved their treat-to-target aim after 12 and 24 weeks of etanercept (ETN) treatment in a real-life setting, as opposed to patients achieving their therapeutic target at a later timepoint (week 36 or 52).
Methods: A total of 824 adults with a confirmed diagnosis of RA without prior ETN treatment were included.